BetterLife Pharma Inc (OTCMKTS: BETRF) Launches a New Website

BetterLife Pharma Inc (OTCMKTS: BETRF) has launched a new website. The website aligns with the company’s goal to make innovative and new therapies for mental health problems like anxiety and depression.

The company is advancing BETR-001 and BETR-002

According to the CEO of BetterLife, Dr. Ahmad Doroudian, the company made progress in advancing the BETR-002 and BETR-001 compounds. Moreover, the preclinical data it has compiled signifies that BETR-001 could treat several mental health disorders.

Since BETR-001 is non-hallucinogenic and uses a non-controlled process of manufacture, the company can produce it faster and use it on various patients. BetterLife uses guidelines from the Food and Drug Administration (FDA) to develop ways for completing its Investigational New Drug Application (NDA). The company hopes to submit this in the second part of 2022.

BetterLife is a biotechnology company focused on developing BETR-002 and BETR-001 to treat

Neurological and neuropsychiatric disorders. BETR-001, which is non-hallucinogenic, is derived from LSD. Furthermore, the patient could administer the drug without supervision since the FDA doesn’t regulate it.

Potential uses of BETR-001 and BETR-002

The company’s BETR-001 patent gets rid of regulatory hurdles. Additionally, BetterLife’s patent-pending for administration method and composition of use shows that the drug can treat post-traumatic stress disorder (PTSD), cluster headaches, depression, and other mental health disorders.

BETR-002 is also in the IND-enabling and preclinical studies. The drug, previously known as TD-010, is derived from honokiol. This substance is the active anxiolytic component in the magnolia bark. The company’s pending formulations and method of use patent show that it treats anxiety disorders such as benzodiazepines dependency.

BetterLife also creates and commercializes other psychedelic products to treat mental health diseases. The company operates in the European Union, Australia, the U.S, and Canada.

BetterLife refined and made potential therapies from several complementary technologies based on interferons. These treatments could improve immunity and help the body fight viral infections like human papillomavirus and coronavirus. It could also help the body fight cancer by inhibiting tumors.

BetterLife and the University of California San Diego have research agreements for a preclinical behavior pharmacological study on TD-0148A. It also has an agreement with Dr. John McCorvy at the Medical College of Wisconsin.